Skip to content
Clinical Trials – home
SpainBack to Spain

Clinical trials in Donostia / San Sebastian – page 20

412 clinical trials in Donostia / San Sebastian, Spain across 2 research sites. Every trial is listed in the EU Clinical Trials Register and updated daily.

SpainOur site in SpainEnsayosClinicos.es(opens in a new tab)
Donostia / San Sebastian at a glance
412
clinical trials
  • Research sites2
Type of trial
Recruitment status
Quick filters

412 trials in Donostia / San Sebastian

Open in trial search

Breast cancer

Not recruiting

Study of Camizestrant plus Ribociclib as First‑Line Treatment for Patients with ER‑Positive, HER2‑Negative Advanced Breast Cancer

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Camizestrant
  • Sponsor:AstraZeneca AB

Narcolepsy

Not recruiting

Efficacy and Safety of E2086 in Adults with Narcolepsy: A Randomized, Double‑Blind, Placebo‑Controlled Trial

Investigational
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Ledasorexton
  • Sponsor:Eisai Limited

Phase III Study Comparing FOLFOX Plus Panitumumab Followed by FOLFIRI Plus Bevacizumab Versus FOLFOX Plus Bevacizumab Followed by FOLFIRI Plus Panitumumab in Wild-Type RAS Metastatic Colorectal Cancer

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Bevacizumab
  • Sponsor:Asociacion Grupo Tratamiento De Tumores Digestivos

Hip fracture

Not recruiting

Efficacy of Tranexamic Acid in Reducing Perioperative Blood Loss in Patients with Hip Fracture: A Randomized, Double-Blind Clinical Trial

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Tranexamic Acid
  • Sponsor:Asociacion Instituto Biogipuzkoa

A Phase 3 Randomized Open-Label Study of Sacituzumab Govitecan Versus Physician's Choice in Recurrent or Persistent Endometrial Cancer Post-Chemotherapy and Immunotherapy

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Paclitaxel
  • Sponsor:Gilead Sciences Inc.

Phase 3 Study of Subcutaneous Pembrolizumab with Hyaluronidase vs. Intravenous Pembrolizumab in Metastatic NSCLC with PD-L1 TPS ≥50%

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Pembrolizumab
  • Sponsor:Merck Sharp & Dohme LLC

A Study of Mevrometostat and Enzalutamide for Men with Metastatic Castration-Sensitive Prostate Cancer Who Have Not Received Hormonal Therapy or Chemotherapy

Registered drug
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Enzalutamide
  • Sponsor:Pfizer Inc.

Study of SAT-3247 Compared to Placebo for Patients with Duchenne Muscular Dystrophy Who Can Walk

Investigational
Countries:SpainSpain
  • Participants:0–17 years
  • Substances:SAT-3247 oxalate
  • Sponsor:Satellos Bioscience Inc.

Breast cancer+1

Not recruiting

Study of Izalontamab Brengitecan Compared to Standard Chemotherapy in Untreated Triple-negative or ER-low, HER2-negative Breast Cancer Patients Not Eligible for Anti-PD1/PD-L1 Treatment

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Capecitabine
  • Sponsor:Bristol-Myers Squibb Services Unlimited Company

Study of RO7126209 safety and effects given by intravenous infusion in patients with early stage or mild to moderate Alzheimer's disease

Investigational
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Flortaucipir (18F)
  • Sponsor:F. Hoffmann-La Roche AG

Cholangiocarcinoma

Not recruiting

Study of cisplatin, gemcitabine and rilvegostomig treatment in patients with high-risk resectable intrahepatic cholangiocarcinoma

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Cisplatin
  • Sponsor:Fondation Franc.Cancerologie Digestive

Study of ifinatamab deruxtecan alone or in combination with other treatments for patients with metastatic castration-resistant prostate cancer

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Abiraterone
  • Sponsor:Merck Sharp & Dohme LLC

Other cities in Spain

The busiest research cities in the country

All 210 cities in Spain

Clinical research in Donostia / San Sebastian

What the registry says about research in the country

01 Neurodegenerative Diseases

Groundbreaking research focusing on Parkinson's disease and Alzheimer's disease, including studies of novel therapeutics and disease-modifying treatments.

  • LRRK2-driven Parkinson's treatment evaluation
  • Early-stage Alzheimer's interventions
  • Down syndrome-associated Alzheimer's research

Multiple trials investigating innovative approaches to manage disease progression and symptoms.

02 Oncology Studies

Comprehensive research into various cancer types, with emphasis on advanced colorectal cancer and melanoma treatments.

  • Targeted therapies for pancreatic adenocarcinoma
  • Brain metastases in melanoma patients
  • Innovative combinations for lymphomas

Focus on personalized treatment approaches and novel drug combinations.

03 Rare Diseases

Specialized research targeting Amyotrophic Lateral Sclerosis (ALS) and other rare conditions, exploring innovative therapeutic approaches.

  • Combined therapy approaches for ALS
  • Soft tissue sarcoma treatments
  • Ocular Myasthenia Gravis studies

Development of targeted therapies for challenging medical conditions.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.